Triptans do not appear to raise the risk of birth defects when taken during pregnancy, based on the accumulated evidence from registry studies and a meta-analysis. That relatively reassuring headline, however, only addresses one piece of a more complicated picture. Questions remain about miscarriage risk, postpartum hemorrhage, and subtle effects on child development. For a pregnant person dealing with severe migraine, the decision about whether to use a triptan involves weighing uncertain but mostly modest risks against the real burden of untreated pain, and understanding what safer alternatives exist.
How Pregnancy Changes Migraine
Most people who get migraines find that their attacks improve during pregnancy, particularly in the second and third trimesters. One study of pregnant women found that about two-thirds reported their headaches decreased during pregnancy, though nearly half still felt anxious about migraine during this time.1PubMed Central. Determination of the Frequency of Migraine Attacks in Pregnant Women and the Ways They Cope with Headaches: A Cross-Sectional Study The improvement is thought to be driven largely by stable, high estrogen levels during pregnancy. Migraine tends to worsen in the postpartum period when those hormone levels crash.2PubMed. Hormone-related headache: pathophysiology and treatment
But improvement is not universal. Roughly a third of pregnant people see no change or worsening, and migraine with aura is less likely to improve than migraine without aura. For those whose attacks persist, finding safe treatment becomes urgent. Severe untreated migraine can lead to dehydration, inability to eat, and significant distress, and migraine itself is associated with pregnancy complications including preeclampsia and preterm birth. In other words, doing nothing about disabling migraine is not automatically the “safe” choice.
How Triptans Work and Why Pregnancy Raises Concerns
Triptans work by activating serotonin receptors, which causes blood vessels around the brain to constrict and calms the overactive nerve signaling that drives a migraine attack.3PubMed Central. Triptans in pregnancy Sumatriptan was the first in the class and remains the most studied in pregnancy.4PubMed. Sumatriptan (Imitrex) transport by the human placenta The concern during pregnancy is twofold. First, vasoconstriction in the uterine or placental blood supply could theoretically reduce blood flow to the fetus. Second, serotonin plays a role in fetal development, so activating serotonin receptors could have downstream effects. These are theoretical concerns, and separating them from what actually happens in real pregnancies has been the focus of two decades of registry data and observational studies.
Birth Defects: The Most Reassuring Evidence
The largest concern for any medication taken in the first trimester is whether it causes structural birth defects. On this question, the evidence for sumatriptan is relatively reassuring. A review in Canadian Family Physician concluded that accumulated data suggest sumatriptan exposure during pregnancy does not increase the risk of birth defects above the baseline rate.5PubMed Central. Safety of triptans for migraine headaches during pregnancy and breastfeeding A meta-analysis comparing triptan-exposed pregnancies to those of women with migraine who did not take triptans found no significant increase in major congenital malformations.6PubMed. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis
A large Norwegian population registry study found something interesting in its comparison groups. When triptan-exposed pregnancies were compared with other pregnancies among women who had migraine, there was no increased risk of congenital malformations. But the group of women with migraine who did not use triptans actually had a higher rate of major malformations compared to the general population, along with higher rates of low birth weight and preterm birth.7European Journal of Epidemiology. Triptan safety during pregnancy: a Norwegian population registry study This is a reminder that migraine itself, and the conditions it travels with, may carry their own risks for pregnancy.
The sumatriptan pregnancy registry data showed that among 479 first-trimester exposures, about 4.6% resulted in major birth defects, which falls within the general population’s background rate of roughly 3 to 5%.8Headache. The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned? Naratriptan data from the same review were more limited but similarly did not show a clear signal. No triptan has robust evidence of causing structural birth defects, though sumatriptan has the most data behind it simply because it has been on the market longest.
Miscarriage Risk: Where the Picture Gets Murkier
When it comes to spontaneous abortion, the data are less comfortable. The same meta-analysis that found no increase in birth defects did find a significantly higher rate of miscarriage among triptan-exposed pregnancies compared with healthy controls, though this difference disappeared when the comparison group was restricted to women who had migraine but did not use triptans.6PubMed. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis That pattern suggests migraine itself, rather than the medication, may partly explain the elevated miscarriage rate.
A more recent matched cohort study using UK primary care records, however, found a modest but statistically significant association between triptan exposure and miscarriage, with adjusted odds about 24% higher than among matched pregnancies that did not end in miscarriage. Interestingly, the same study found a similar-sized association for amitriptyline and a larger one for NSAIDs.9PubMed. Migraine, associated treatments and risk of miscarriage: A matched cohort study and nested case-control study using the CPRD pregnancy register These are observational findings and cannot prove causation. Women who take triptans during early pregnancy may have more severe migraine, more stress, or other factors that independently increase miscarriage risk. But the signal is consistent enough that clinicians take it seriously, especially in the first trimester.
Preterm Birth and Postpartum Bleeding
Triptans have not been consistently linked to preterm birth. A study comparing triptans to dihydroergotamine found no statistically significant increase in prematurity with triptan use, whereas dihydroergotamine use carried a substantially higher risk.10Scientific Reports. Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes The Norwegian registry data similarly showed no increase in preterm birth for triptan users compared to other women with migraine.7European Journal of Epidemiology. Triptan safety during pregnancy: a Norwegian population registry study
Postpartum hemorrhage is a different matter. Data from the Norwegian Mother and Child Cohort Study found that triptan use during the second or third trimester was associated with a roughly 40% higher risk of atonic uterus (when the uterus fails to contract properly after delivery) and about a 30% higher risk of blood loss exceeding 500 mL during labor.11PubMed. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study A separate analysis from the same Norwegian registry found a similar association between second-trimester triptan use and postpartum hemorrhage, and noted that the mechanism could involve changes in platelet function seen in severe migraine rather than a direct drug effect.12PubMed. Triptan safety during pregnancy: a Norwegian population registry study This is one of the more concrete safety signals for later-pregnancy triptan use, even if the absolute risk remains relatively low.
Effects on Child Development
A growing number of studies have looked beyond birth outcomes to ask whether prenatal triptan exposure affects children’s neurological development in the years afterward. A 2022 study found no increased risk of ADHD diagnosis in children whose mothers took triptans during pregnancy, whether compared with unexposed children of mothers who had migraine during pregnancy or children of mothers who had migraine only before pregnancy.13JAMA Network Open. Association of Maternal Use of Triptans During Pregnancy With Risk of Attention-Deficit/Hyperactivity Disorder in Offspring
A broader 2025 study looking at various neurodevelopmental outcomes found only slightly elevated risks that shrank to essentially nothing once the comparison group was narrowed to women who had used triptans before pregnancy but stopped. The study found a small, non-significant trend toward autism spectrum diagnoses in children whose mothers continued triptans late into pregnancy, but the confidence intervals were wide and the absolute risk difference was small.14PubMed. Association of Prenatal Exposure to Triptans, Alone or Combined With Other Migraine Medications, and Neurodevelopmental Outcomes in Offspring
One Norwegian cohort study did report that children with prenatal triptan exposure showed greater increases in emotionality and activity-related behavior problems between 18 and 36 months of age, compared with children of mothers who stopped triptans before pregnancy.15BMJ Open. Longitudinal changes in neurodevelopmental outcomes between 18 and 36 months in children with prenatal triptan exposure: findings from the Norwegian Mother and Child Cohort Study The effect sizes were modest, and the study could not determine whether the differences were caused by the medication, the underlying migraine severity, or other lifestyle factors. Overall, the developmental research so far does not show a clear, consistent harm, but it has not definitively ruled out subtle effects either. This remains an active area of study.
Migraine Itself Carries Pregnancy Risks
One of the most important things to understand about triptan safety data is the confounding problem. Women who take triptans during pregnancy have migraine. Women who have migraine, particularly migraine with aura, face elevated risks for pregnancy complications independent of any medication. A study from Peru found that women with migraines before pregnancy had a 3.5-fold increased risk of preeclampsia, and women with active migraines during pregnancy had a 4-fold increased risk.16American Journal of Hypertension. Headaches and Migraines Are Associated With an Increased Risk of Preeclampsia in Peruvian Women An Indian case-control study similarly found a strong association between migraine history and preeclampsia.17PubMed Central. Association between migraine and pre-eclampsia among pregnant women: a single hospital-based case-control study in India An epidemiological review suggested that migraine and preeclampsia may share an underlying predisposition related to vascular and endothelial function.18PubMed. Migraine headaches and preeclampsia: an epidemiologic review
This matters because when a study finds that triptan-exposed pregnancies have more complications, it can be difficult to tease apart how much is the drug and how much is the disease. The Norwegian registry study highlighted this explicitly: the migraine-without-triptan group had worse outcomes than the general population, suggesting that migraine itself is the primary driver of excess risk in many cases. Careful management of migraine in pregnancy is warranted not only to relieve symptoms but potentially to reduce complications associated with the condition itself.
Safer Alternatives for Acute Attacks
When migraine strikes during pregnancy, acetaminophen (paracetamol) is the first-line treatment. A review of migraine treatment in pregnancy identified 1,000 mg of acetaminophen, preferably as a suppository for better absorption during nausea, as the safest initial option.19PubMed. Migraine in pregnancy: what are the safest treatment options? The reality, of course, is that acetaminophen alone is often inadequate for moderate-to-severe migraine. Prescribing data confirm this gap: among women with migraine, acetaminophen was the most commonly used medication in both the pre-pregnancy period and the first trimester, but sumatriptan remained the second most common choice in the first trimester despite the concerns around it.20PubMed Central. Use of antimigraine medication before pregnancy and in the first trimester: A cross-sectional study
NSAIDs such as ibuprofen are considered relatively safe during the first and second trimesters when used occasionally, but they carry specific risks in the third trimester. A meta-analysis found that NSAID exposure in late pregnancy was associated with a substantially higher risk of premature closure of the ductus arteriosus, a critical fetal blood vessel that is supposed to remain open until birth.21PubMed. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis A German cohort study confirmed that ductus arteriosus constriction, while uncommon overall, occurred in NSAID-exposed pregnancies and not in unexposed ones, and that one case appeared as early as the late second trimester after prolonged NSAID use.22PubMed Central. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort The bottom line: ibuprofen can fill a gap in early pregnancy but should be avoided after about 20 weeks, and certainly in the third trimester.
Anti-nausea medications can also help. Metoclopramide is generally considered acceptable during the second and third trimesters, and prochlorperazine (often given in emergency departments for severe migraine) is unlikely to be harmful during pregnancy.19PubMed. Migraine in pregnancy: what are the safest treatment options? These antiemetics can relieve migraine-associated nausea and may have some independent anti-migraine effect.
Non-Drug Approaches
Current guidance emphasizes prioritizing non-pharmacological approaches when migraine persists during pregnancy, starting with lifestyle modifications and behavioral therapies. Non-invasive neuromodulation is also considered a reasonable option in some cases.23SAGE Journals (Cephalalgia). Migraine management during pregnancy, breastfeeding and in women planning pregnancy That said, the same guidance acknowledges that disabling migraine should not be left untreated and may require medication.
Procedural options can be surprisingly effective. A retrospective study of occipital nerve blocks in pregnant women found that pain scores dropped from an average of 7 out of 10 before the procedure to 2 out of 10 afterward, and the number of days per month needing acute medication roughly halved.24PubMed Central. A retrospective cohort study to evaluate the effectiveness and safety profile of occipital nerve blocks in the treatment of migraine during pregnancy Nerve blocks use local anesthetic injected near specific nerves in the head and neck, and because the medication stays local rather than circulating through the entire body, the fetal exposure is minimal. Other options including trigger point injections, sphenopalatine ganglion blocks, and expanding neurostimulation technologies offer additional non-systemic treatment avenues, though the evidence base is still building.25PubMed. Integrative, Interventional, and Non-invasive Approaches for the Treatment for Migraine During Pregnancy
What About the Newer CGRP-Blocking Drugs?
CGRP antagonists, the class that includes gepants (like rimegepant and ubrogepant) and monoclonal antibodies (like erenumab and fremanezumab), have revolutionized migraine treatment in recent years. But their safety during pregnancy is essentially unknown. A pharmacovigilance analysis looking at pregnancy-related adverse event reports found no clear difference in reporting frequency between CGRP antagonists and triptans, but the authors were careful to note that current evidence on CGRP antagonist safety in human pregnancy does not yet provide definitive information.26PubMed Central. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase CGRP itself plays a role in placental development, which raises theoretical concerns about blocking it during pregnancy. For now, most guidelines recommend discontinuing CGRP-targeting medications before conception, and they are not recommended during pregnancy. The monoclonal antibodies are particularly problematic because their half-lives are measured in weeks, meaning the drug lingers long after the last dose.
How Prescribing Patterns Have Shifted
Despite the uncertainties, triptan prescribing to pregnant women has slowly increased over time. UK prescribing data show that the proportion of pregnant women prescribed triptans rose from about 2.3% in 2000 to about 3.7% in 2018, with first-trimester prescriptions showing a similar upward trend.27Journal of Neurology, Neurosurgery & Psychiatry. Trends in the prevalence and pharmacological management of migraine during pregnancy in the UK, 2000–2018 This likely reflects growing comfort with the accumulated safety data rather than a change in guidelines, which generally still position triptans as a second-line option during pregnancy.
Most women who used triptans before pregnancy do stop them, however. Among women with migraine, triptans were the most commonly filled prescription before pregnancy, but they were frequently discontinued early in pregnancy along with antidepressants and antiepileptic drugs.28PubMed Central / SAGE Journals. Polypharmacy and comorbidities during pregnancy in a cohort of women with migraine A cross-sectional study found that sumatriptan use dropped from about 12% of women with migraine before pregnancy to about 3% in the first trimester.20PubMed Central. Use of antimigraine medication before pregnancy and in the first trimester: A cross-sectional study The sharp drop in ibuprofen use (from about 26% to under 1%) is even more striking and reflects the clearer warnings about NSAIDs.
Triptans and Breastfeeding
After delivery, the calculus changes. Migraine frequently rebounds in the postpartum period, and many new parents need effective treatment while breastfeeding. The news here is encouraging. A study that measured triptan concentrations in breast milk found that for most triptans, the infant’s estimated drug exposure was well below 10% of the weight-adjusted maternal dose, which is the general threshold used to judge breastfeeding compatibility. Eletriptan and sumatriptan had the lowest transfer rates, at roughly 0.6% and 0.7% respectively. Naratriptan was the highest at about 5%, making it a less ideal first choice during the neonatal period when the infant’s ability to clear drugs is still developing.29PubMed. Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding Overall, the amounts transferred into breast milk appear insufficient to cause adverse effects in the nursing infant.5PubMed Central. Safety of triptans for migraine headaches during pregnancy and breastfeeding
Sumatriptan in particular is often cited as compatible with breastfeeding, and some headache specialists specifically recommend it as a first-line acute treatment during lactation.30PubMed. Treatment of cluster headache in pregnancy and lactation If you were using triptans before pregnancy and stopped during gestation, restarting after delivery is generally considered reasonable. The one caveat: individual infants process drugs differently, so monitoring for any unexplained symptoms in the newborn is still sensible, particularly in the first few weeks of life when liver and kidney function are still maturing.
When Triptans May Still Be the Right Choice During Pregnancy
The honest clinical reality is that some pregnant people have migraine that does not respond to acetaminophen, cannot be managed with nerve blocks alone, and leaves them unable to eat, drink, or function. In these cases, untreated migraine carries its own risks: dehydration, malnutrition, repeated emergency department visits, and the stress and vascular effects of severe pain. Current expert opinion, as reflected in recent guidelines, holds that disabling migraine should not simply be left untreated during pregnancy and may require pharmacological management when non-drug options fail.23SAGE Journals (Cephalalgia). Migraine management during pregnancy, breastfeeding and in women planning pregnancy
For those situations, sumatriptan remains the triptan with the most pregnancy safety data and is the one most clinicians reach for when a triptan is needed. The decision is always individualized, considering the trimester, the severity and frequency of attacks, what has already been tried, and the person’s own comfort level with the available evidence. If you are pregnant or planning to become pregnant and currently rely on triptans, the conversation with your prescriber is about building a stepwise plan rather than simply stopping all effective treatment and hoping for the best.